British pharmaceutical company AstraZeneca is resuming trials with a possible corona vaccine. The company says this in a statement.
–
On Wednesday, the tests were temporarily halted due to medical problems with a subject (DS September 10, 2020). AstraZeneca, which is developing the vaccine together with Oxford University, has now received approval from the British Medicines Health Regulatory Authority (MHRA) to resume trials.
It is not uncommon for tests to stop temporarily in the event of medical problems. Independent committees and regulators must evaluate the data before the trials can resume. And that has now happened, says AstraZeneca.
It is not said exactly what happened to the test subject. But according to American media, a woman had developed an inflammation of the spinal cord. She would be getting better.
“All researchers and test subjects will receive an update with all relevant information,” the pharmaceutical company said.
Leader
AstraZeneca is said to be one of the front runners in the race for the vaccine. Today, AstraZeneca’s ‘AZD1222’ is one of the few vaccine candidates in the final phase of the investigation before drug agencies review the files and, at best, approve them for sale. The company also took the lead in negotiating agreements with governments for the supply of large quantities of the vaccine. It has already made deals with the US, UK and Japanese governments and with the European Commission. 7.5 million doses have been reserved for Belgium.
Nine major American and European pharmaceutical companies, including AstraZeneca, wrote in an open letter on Tuesday that they will not market their coronavirus vaccines until they prove safe and effective. The document was intended to counter the perception that health risks are being taken in order to get a corona vaccine on the market as soon as possible. The trust of the general public is necessary because a large proportion of people will have to use the tool to make it effective.
– .
